MRI-guided biopsy of the prostate: Correlation between the cancer detection rate and the number of previous negative TRUS biopsies

Diagnostic and Interventional Radiology

Volumn 19, Issue 5, 2013, Pages 411-417

  Durmuş, Tahir ^a   Reichelt, Uta ^a   Huppertz, Alexander ^a   Hamm, Bernd ^a   Beyersdorff, Dirk ^a   Franiel, Tobias ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin's Charite Hospital ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOPSY DEVICE; CONTROLLED STUDY; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; TRANSRECTAL ULTRASONOGRAPHY;

AGED; BIOPSY; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMAGE-GUIDED BIOPSY; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATIC NEOPLASMS; RECTUM; REPRODUCIBILITY OF RESULTS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84883375687     PISSN: 13053825     EISSN: 13053612     Source Type: Journal    
DOI: 10.5152/dir.2013.13055     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300. [CrossRef]
2. Farwell WR, Linder JA, Jha AK. Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med 2007; 167:2497-2502. [CrossRef]
3. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:120-134. [CrossRef]
4. Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001; 166:1679-1683. [CrossRef]
5. Bouye S, Potiron E, Puech P, Leroy X, Lemaitre L, Villers A. Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology. Prostate 2009; 69:105-113. [CrossRef]
6. Eskicorapci SY, Baydar DE, Akbal C, et al. An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 2004; 45:444-449. [CrossRef]
7. Pepe P, Aragona F. Prostate needle biopsy: 12 vs. 18 cores--is it necessary? Urol Int 2005; 74:19-22. [CrossRef]
8. de la Taille A, Antiphon P, Salomon L, et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 2003; 61:1181-1186. [CrossRef]
9. Heijmink SW, Barentsz JO. Contrast-enhanced versus systematic transrectal ultrasound-guided prostate cancer detection: an overview of techniques and a systematic review. Eur J Radiol 2007; 63:310-316. [CrossRef]
10. Hong YM, Lai FC, Chon CH, McNeal JE, Presti JC Jr. Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies. Urol Oncol 2004; 22:7-10. [CrossRef]
11. Franiel T, Stephan C, Erbersdobler A, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning. Radiology 2011; 259:162-172. [CrossRef]
12. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology 2010; 255:89-99. [CrossRef]
13. Turkbey B, Bernardo M, Merino MJ, Wood BJ, Pinto PA, Choyke PL. MRI of localized prostate cancer: coming of age in the PSA era. Diagn Interv Radiol 2012; 18:34-45.
14. Iwazawa J, Mitani T, Sassa S, Ohue S. Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging? Diagn Interv Radiol 2011; 17:243-248.
15. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164:400-404. [CrossRef]
16. Mullerad M, Hricak H, Kuroiwa K, et al. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol 2005; 174:2158-2163. [CrossRef]
17. Kumar V, Jagannathan NR, Kumar R, et al. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml. NMR Biomed 2007; 20:11-20. [CrossRef]
18. Yagci AB, Ozari N, Aybek Z, Duzcan E. The value of diffusion-weighted MRI for prostate cancer detection and localization. Diagn Interv Radiol 2011; 17:130-134.
19. Beyersdorff D, Winkel A, Hamm B, Lenk S, Loening SA, Taupitz M. MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology 2005; 234:576-581. [CrossRef]
20. Hambrock T, Futterer JJ, Huisman HJ, et al. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol 2008; 43:686-694. [CrossRef]
21. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991; 17:357-367. [CrossRef]
22. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996; 198:795-805.
23. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21:2163-2172. [CrossRef]
24. Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997; 50:562-566. [CrossRef]
25. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157:199-202. [CrossRef]
26. Taylor JA 3rd, Gancarczyk KJ, Fant GV, McLeod DG. Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. Urology 2002; 60:841-845. [CrossRef]
27. Park BK, Lee HM, Kim CK, Choi HY, Park JW. Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy. Invest Radiol 2008; 43:789-793. [CrossRef]
28. Anastasiadis AG, Lichy MP, Nagele U, et al. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 2006; 50:738-739. [CrossRef]
29. Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010; 183:520-527. [CrossRef]
30. Roethke M, Anastasiadis AG, Lichy M, et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2012; 30:213-218. [CrossRef]
31. Engelhard K, Hollenbach HP, Kiefer B, Winkel A, Goeb K, Engehausen D. Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device. Eur Radiol 2006; 16:1237-1243. [CrossRef]
32. Deliveliotis C, Varkarakis J, Albanis S, Argyropoulos V, Skolarikos A. Biopsies of the transitional zone of the prostate. Should it be done on a routine basis, when and why? Urol Int 2002; 68:113-117. [CrossRef]
33. Scheidler J, Weores I, Brinkschmidt C, et al. Diagnosis of prostate cancer in patients with persistently elevated PSA and tumor-negative biopsy in ambulatory care: performance of MR imaging in a multi-reader environment. Rofo 2012; 184:130-135. [CrossRef]
34. Singh AK, Kruecker J, Xu S, et al. Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int 2008; 101:841-845. [CrossRef]
35. Durmus T, Stephan C, Grigoryev M, et al. Detection of prostate cancer by real-time MR/ultrasound fusion-guided biopsy: 3T MRI and state of the art sonography. Rofo 2013; 185:428-433.